These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 30265552

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M, Umbricht CA, Schibli R, Müller C.
    Mol Pharm; 2018 Mar 05; 15(3):934-946. PubMed ID: 29400475
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.
    Müller C, Bunka M, Reber J, Fischer C, Zhernosekov K, Türler A, Schibli R.
    J Nucl Med; 2013 Dec 05; 54(12):2168-74. PubMed ID: 24198390
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 9. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
    Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R.
    J Nucl Med; 2013 Jan 04; 54(1):124-31. PubMed ID: 23236020
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.
    Bailey GA, Price EW, Zeglis BM, Ferreira CL, Boros E, Lacasse MJ, Patrick BO, Lewis JS, Adam MJ, Orvig C.
    Inorg Chem; 2012 Nov 19; 51(22):12575-89. PubMed ID: 23106422
    [Abstract] [Full Text] [Related]

  • 13. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 14. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
    Hoppmann S, Qi S, Miao Z, Liu H, Jiang H, Cutler CS, Bao A, Cheng Z.
    J Biol Inorg Chem; 2012 Jun 05; 17(5):709-18. PubMed ID: 22418921
    [Abstract] [Full Text] [Related]

  • 15. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.
    Nucl Med Biol; 2009 Aug 05; 36(6):591-603. PubMed ID: 19647165
    [Abstract] [Full Text] [Related]

  • 16. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2.
    Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E.
    Molecules; 2024 Jun 28; 29(13):. PubMed ID: 38999044
    [Abstract] [Full Text] [Related]

  • 17. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation.
    Feng L, Hu W, Zeng X, Wei Z, Long Y, Li M, Sun S, Guo Z, Lan X, Zhang X, Zhuang R, Jiang D.
    Mol Pharm; 2024 Sep 02; 21(9):4386-4394. PubMed ID: 39046432
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
    Joosten L, Frielink C, Jansen TJP, Lobeek D, Andreae F, Konijnenberg M, Heskamp S, Gotthardt M, Brom M.
    Mol Pharm; 2023 Jul 03; 20(7):3519-3528. PubMed ID: 37265006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.